[Spasmolytic effect of 5,5-diphenyl-2-(2'-piperidino-ethyl)-1,3-dioxclan-4-one HCl, a new spasmolytic].
D000109:Acetylcholine / Q000037:antagonists & inhibitors; D000818:Animals; D001285:Atropine / Q000494:pharmacology*; D001464:Barium / Q000037:antagonists & inhibitors; D001775:Blood Circulation / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D002217:Carbachol / Q000037:antagonists & inhibitors; D002415:Cats; D002712:Chlorides / Q000037:antagonists & inhibitors; D003864:Depression, Chemical; D004149:Dioxoles / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000633:toxicity; D004423:Ear / Q000187:drug effects; D004837:Epinephrine / Q000037:antagonists & inhibitors; D005260:Female; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects; D006614:Hindlimb / Q000187:drug effects; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D007422:Intestines / Q000187:drug effects; D008297:Male; D051379:Mice; D009388:Neostigmine / Q000037:antagonists & inhibitors; D010208:Papaverine / Q000494:pharmacology*; D010276:Parasympatholytics / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D012119:Respiration / Q000187:drug effects; D012601:Scopolamine / Q000494:pharmacology*; D013997:Time Factors
D002712:Chlorides; D004149:Dioxoles; D006634:Histamine H1 Antagonists; D010276:Parasympatholytics; D001464:Barium; D009388:Neostigmine; D001285:Atropine; D002217:Carbachol; D010208:Papaverine; D012601:Scopolamine; D000109:Acetylcholine; D004837:Epinephrine
Zur spasmolytischen Wirkung von 5,5-Diphenyl-2-(2'-piperidino-äthyl)-1,3-dioxolan-4-on HCl, ein neues Spasmolyticum.